U.S. panel to consider approval of Roche's Actemra in July

06/5/2008 | Reuters

The FDA's Arthritis Advisory Committee is scheduled on July 29 to review Roche Holding's Actemra for approval. The company believes that the drug, which has been approved in Japan, will gain competitive advantage as an alternative to anti-tumor necrosis factor drugs used in rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA